Quantcast
Last updated on April 18, 2014 at 1:21 EDT

International pharmaceutical company, Almirall, expands global footprint with new Canadian affiliate

September 5, 2013

New affiliate to support forthcoming Canadian product launches

TORONTO, Sept. 5, 2013 /CNW/ – Almirall, the international
pharmaceutical company based in Barcelona, Spain, continued its
expansion with the launch of a new affiliate in Canada, the world’s
seventh largest pharmaceutical market. The Canadian affiliate will
focus primarily on the respiratory and dermatology therapeutic areas.

General Manager for Almirall Canada, Ed Dybka, commented: “This is a very exciting time for Almirall.  Pipeline advances, key
regulatory milestones and collaboration agreements have set the stage
for a period of sustained international growth.  Our launch in Canada
will contribute to this growth and emphasizes our commitment to the
North American pharmaceutical market.”

Based in Mississauga, the new affiliate will support the Canadian
launches of new Almirall products including an innovative new treatment
for chronic obstructive pulmonary disease (COPD), TudorzaTM GenuairTM,
which will launch in the fall.

Almirall Canada is the company’s 13th affiliate joining affiliates
across Europe and Mexico

Building on Almirall’s long history of success in Europe; “We aim to stand apart as a pharmaceutical company in Canada by being
easy to do business with, and passionate and genuine in our commitment
to partner with the medical community to improve the lives of Canadian
patients,”
Dybka said.  “We welcome Canada’s best and brightest to help us achieve this.”

Research and development

Research has been core to Almirall’s DNA for over 40 years.  In 2012,
Almirall reinvested more than 23 per cent of its sales in R&D – an
increase of 10 per cent from the previous year.  This was the highest
investment in R&D by any pharmaceutical company in Spain and ranked it
third of all industrial companies in the country.

By the end of 2012, 20 per cent of all company personnel were dedicated
to R&D. The 500-plus scientists and experts at Almirall play an
essential role in all product phases, from the research and development
to registration applications for marketing authorisation.

Corporate values

Almirall’s corporate values define our culture; the way we work and how
we interact on a professional and personal level.  They help set us
apart from our competitors, channelling the organisation’s collective
efforts to establish a unique position.

Our four values; trust, innovation, partnership and personal
accountability, define the company, help boost our performance and
generate value. The company’s results are the sum total of individual
efforts devoted to fulfilling our vision, targets and goals.

About Almirall

Almirall is a pharmaceutical company committed to providing valuable
medicines through our own R&D efforts, which exceeded 23 per cent of
sales in 2012, together with external partnerships, licenses and
collaborations. We seek to provide innovative medicines to treat
respiratory and dermatology diseases, with a strong interest in
gastroenterology and pain.

With more than 3000 employees in 22 countries, Almirall generated total
revenues that exceeded 1 billion dollars in 2012.

The company was founded in 1943 and is headquartered in Barcelona,
Spain. The stock is traded on the Spanish stock exchange (ticker: ALM).

For more information please visit www.almirall.com

SOURCE Almirall


Source: PR Newswire